The efficacy and safety of belzutifan inhibitor in patients with advanced or metastatic clear cell renal cell carcinoma: a meta-analysis

Table 2 Total treatment-related adverse effects in mccRCC patients

Adverse events	Studies involved	Event/Total	%
Circulatory system AEs
Anemia	7	599/713	84.01
Hypertension	3	87/132	65.91
Thrombocytopenia	1	13/50	26
Edema	5	92/581	15.83
Decreased lymphocyte count	1	4/55	7.27
Decreased platelet count	1	3/55	5.45
Digestive system AEs
Dysgeusia	1	25/50	50
Nausea	7	181/713	25.39
Diarrhoea	6	151/713	21.18
Decreased appetite	7	134/713	18.79
Increased alanine aminotransferase	6	111/683	16.25
Increased aspartate aminotransferase	6	104/683	15.23
Vomiting	3	64/477	13.42
Constipation	3	68/526	12.93
Stomatitis	2	23/422	5.45
Endocrine system AEs
Hypophosphataemia	2	29/102	28.43
Hypothyroidism	1	11/50	22
Increased blood creatinine	2	35/427	8.2
Hemoglobin decreased	2	12/154	7.79
Hypertriglyceridemia	1	14/372	3.76
Increased blood alkaline phosphatase	1	3/55	5.45
Hypercalcemia	1	2/55	3.64
Hyperglycemia	1	10/372	2.69
Skin AEs
Palmar–plantar erythrodysesthesia	2	51/102	50
Pruritus	3	35/526	6.65
Rash	1	17/372	4.57
Nervous system AEs
Fatigue	7	326/713	45.72
Headache	4	67/581	11.53
Dizziness	4	65/581	11.19
Respiratory system AEs
Dyspnea	4	87/526	16.54
Cough	4	41/581	7.06
Pneumonitis	2	6/427	1.41
Locomotor system AEs
Arthralgia	1	54/372	14.52
Myalgia	3	11/209	5.26
Muscular weakness	1	2/55	3.64
Others AEs
Proteinuria	2	36/85	42.35
Weight decreased	1	11/50	22
Hypoxia	4	105/526	19.96
Back pain	1	55/372	14.78
Asthenia	4	61/581	10.5
Pyrexia	1	22/372	5.91
Increased weight	2	7/133	5.26
Flushing	1	2/55	3.64
Malaise	1	2/55	3.64

Abbreviations AEs adverse effects, mccRCC advanced or metastatic clear cell renal cell carcinoma

ISSN: 2050-6511